东微半导公告称，公司于2025年12月3日召开相关会议，审议通过2026年度日常关联交易预计议案。 2026年1-7月预计与关联方客户A出售商品及服务金额1.55亿元，占同类业务比例15.45%；2025年1-10月 实际发生9845.86万元，占比9.81%。公司与客户A关联关系将于2026年7月底解除。该事项尚需股东会 审议，关联股东需回避表决。保荐机构中金公司同意上述预计事项。 ...

东脑智合方面表示，将充分利用上海在人才、资本及产业链配套方面的综合优势，依托脑智天地打造的开放创新平台，加快技术转化和产品化进程，并积极 参与国内外标准制定与产业生态构建。据悉，2025年全国脑机接口大会将于12月初在脑智天地举办，届时全球脑机接口领域的专家学者和前沿科技团队将齐 聚闵行，共同探讨脑机接口未来产业在中国的应用前景与发展路径。 （校对/秋贤） 公开信息显示，东脑智合汇聚了半导体与神经科学领域的多位顶尖人才。创始人龚轶在模拟芯片、功率器件等半导体领域深耕多年，拥有扎实的技术积累和 产业化经验。公司还引入了国际上经验丰富的生物传感器芯片开发团队，在超低功耗、高通量脑专用芯片和系统的底层架构定义与开发上开展协同攻关。 在电极技术方面，东脑智合的核心团队由中国科学院半导体所研究员、中国科学院大学岗位教授裴为华领衔，其在神经接口技术领域已深耕20余年，现任中 国脑机接口产业联盟硬件组副主席。公司表示，将以全球独创的液压驱动柔性神经触手电极技术为核心，面向科研级和医疗级场景，推进侵入式脑机接口全 栈式核心技术布局，目标是成长为全球顶尖的脑机接口企业之一。 （文/罗叶馨梅）近日，据上海脑机接口未来产业集聚区（ ...

据了解，东脑智合汇聚了半导体和神经科学领域的顶尖人才。创始人龚轶先生同时担任东微半导（股票 代码：688261.SH）董事长，在半导体领域积累了深厚的技术功底。东脑智合引入国际上经验丰富的生 物传感器芯片开发资深团队，在芯片底层技术上实现超低功耗高通量脑专用芯片和系统的定义和开发。 据悉，12月初，2025年全国脑机接口大会将在脑智天地集聚区举办，届时，全球的脑机接口专家和前沿 科技人才都将汇聚于此，共同畅想脑机接口未来产业在中国的发展和应用。 电极技术核心技术团队由中国科学院半导体所研究员、国科大岗位教授裴为华领衔。裴为华致力于神经 接口技术研究20余年，现担任中国脑机接口产业联盟硬件组副主席。 （文章来源：证券时报网） 东脑智合表示，作为一家专注于侵入式脑机接口技术研发的创新企业，公司以全球独创的液压驱动柔性 神经触手电极技术为核心，致力于发展科研级和医疗级侵入式脑机接口全栈式核心技术，目标成为全球 顶尖的脑机接口公司。 近日，上海东脑智合技术有限公司（以下简称"东脑智合"）完成注册，正式落地全国首个以脑机接口技 术发展为目标的特色产业集聚区——上海脑机接口未来产业集聚区（脑智天地）。 "十二五 "以来， ...

Core Viewpoint - The company focuses its business primarily on the domestic market, with a low proportion of overseas sales [2] Summary by Relevant Sections - **Business Focus** - The company's operations are concentrated in the domestic market, indicating a strategic choice to prioritize local opportunities over international expansion [2]

证券代码：688261 证券简称：东微半导 公告编号：2025-050 苏州东微半导体股份有限公司 关于举办 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 会议问题征集：投资者可于 2025 年 11 月 21 日（星期五）14:00 点前访 问网址 https://eseb.cn/1t8J593VBe0 或使用微信扫描下方小程序码进行会前 提问，公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的 问题进行回答。 一、说明会类型 苏州东微半导体股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日在上海证券交易所网站（www.sse.com.cn）披露了《苏州东微半导体股份有限 公司 2025 年第三季度报告》。为便于广大投资者更加全面深入地了解公司经营业 绩、发展战略等情况，公司定于 2025 年 11 月 21 日（星期五）15:00-16:00 在 "价值在线"（www.ir-online.cn）举办 2025 年第三季度业绩说 ...

Group 1 - Dongwei Semiconductor (688261.SH) closed at 66.91 yuan, with a decline of 2.25% [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on February 10, 2022, issuing 16.844092 million shares, accounting for 25.00% of the total shares post-issuance, at a price of 130.00 yuan per share [1] - Currently, the stock is in a state of decline from its initial offering price [1] Group 2 - The total funds raised by Dongwei Semiconductor during its IPO amounted to 2.19 billion yuan, with a net amount of 2.007 billion yuan after deducting issuance costs, which was 1.068 billion yuan more than the original plan of 939 million yuan [1] - The funds are intended for upgrading and industrialization of super junction and shielding gate power devices, R&D of new structure power devices, and construction of a research and development engineering center [1] - The total issuance costs were 183 million yuan, with the lead underwriter, China International Capital Corporation, receiving 156 million yuan in underwriting fees [1] Group 3 - The company announced a cash dividend of 1.476 yuan per share (including tax) and a capital reserve transfer of 0.4 shares for every share held, resulting in a total cash dividend distribution of approximately 99.45 million yuan and a transfer of 26.95 million shares [2] - Following this distribution, the total share capital will increase to 94,326,914 shares [2] - For the 2023 annual dividend distribution, the company plans to distribute 1.79 yuan in cash for every 10 shares and transfer 3 shares for every 10 shares held, with the record date set for July 3, 2024 [2]

Core Viewpoint - The Chinese innovative drug market is entering a rapid development phase, with local leading companies like Heng Rui benefiting from policy support and industry expansion opportunities [1] Company Performance - Heng Rui Pharmaceutical reported a revenue of 23.188 billion yuan for the first three quarters of 2025, a year-on-year increase of 14.85%, and a net profit of 5.751 billion yuan, up 24.50% [2] - The company has received a total cash dividend of over 9.3 billion yuan, enhancing investor returns [1] - The company has established a differentiated competitive advantage through over 50 billion yuan in R&D investment and has 24 innovative drugs approved for sale in China [1] Industry Trends - The innovative drug sector is experiencing accelerated commercialization and increased business development (BD) transactions, leading to a sustained trend of rapid growth in performance [1] - Other innovative drug companies, such as Zai Lab and DiZhe Pharmaceutical, are also reporting significant revenue growth, with Zai Lab achieving a 54.49% increase in revenue to 593 million yuan [3] - The industry is expected to continue its growth trajectory, supported by favorable national policies and increasing international collaboration [4][5] R&D Focus - Heng Rui's innovative drugs, including Rivoceranib and Darsylis, are addressing unmet clinical needs, contributing to their revenue growth [2] - Zai Lab emphasizes its differentiated product pipeline focusing on oncology and autoimmune diseases, aiming to fill domestic gaps in treatment options [3] - The industry is witnessing a rise in R&D investments, with companies like Yi Fang Bio reporting a total R&D investment of 190 million yuan for the first three quarters of 2025 [4] Future Outlook - Analysts predict a new round of growth for the pharmaceutical sector, particularly in innovative drugs, as the international standing of Chinese innovative drug companies rises [5] - The innovative drug sector is expected to remain a key investment theme in the pharmaceutical industry through 2026, driven by increased BD transactions and international collaborations [5]

Summary of Conference Call Company Overview - **Company**: Dongwei Peninsula - **Industry**: Power Semiconductor Design Key Financial Highlights - **Revenue**: - For the first nine months, revenue reached 963 million yuan, a year-on-year increase of 41.6% [2][3] - Third-quarter revenue was 348 million yuan, a year-on-year growth of 3% [2] - **Net Profit**: - Net profit attributable to shareholders for the first nine months was 48.55 million yuan, up 58.46% year-on-year [2] - Third-quarter net profit was approximately 20.9 million yuan, a year-on-year increase of 53.09% [2] - **Non-recurring Profit**: - Non-recurring net profit for the first nine months was 20.38 million yuan, a significant increase of 374.48% [2] - Non-recurring net profit for the third quarter was 16.44 million yuan, up 524.69% year-on-year [3] Product and Market Insights - **Product Segmentation**: - Core products include Superjet, accounting for over 70% of revenue, and medium-low voltage shielding products, which exceeded 20% [6][7] - AI-related products are categorized under industrial and communication power supplies, contributing significantly to revenue [8] - **Growth Areas**: - The company has seen substantial growth in new power device modules, with revenue reaching over 10 million yuan [7] - AI-related revenue is expected to grow, with a stable upward trend in demand across various sectors [8] Supply Chain and Cost Management - **Supply Chain Strategy**: - The company is actively stocking up on wafer resources, particularly 12-inch wafers, to meet future demand [19][20] - Inventory levels have increased, reflecting a strategic decision to prepare for anticipated demand, especially in AI [18][19] - **Gross Margin**: - Average gross margin for the third quarter was around 16%, showing a slight year-on-year increase of 1.01 percentage points [11] Future Outlook - **Quarterly Projections**: - The company expects to maintain a stable revenue distribution, with the fourth quarter traditionally accounting for a higher percentage of annual revenue [16][17] - **Product Development**: - Focus on GaN (Gallium Nitride) technology is a priority, with ongoing partnerships and product development expected to yield results in the coming year [22][23] - **Market Positioning**: - The company aims to leverage its strengths in low-voltage products and expand into new markets, particularly in the context of increasing electrification and battery usage [30][31] Additional Insights - **Strategic Partnerships**: - Collaborations with leading semiconductor manufacturers and suppliers are being established to enhance product offerings and market competitiveness [22][26] - **Investment in R&D**: - The company is committed to investing in advanced technologies and projects to ensure long-term growth and innovation [31] This summary encapsulates the key points discussed during the conference call, highlighting the company's financial performance, product insights, supply chain strategies, and future outlook.

Core Viewpoint - The company has reported its third-quarter financial results, including the recognition of asset impairment provisions totaling 5,943,632.83 yuan, reflecting a cautious approach to financial reporting and asset valuation [12][13][15]. Financial Data - The company has not conducted an audit for the third-quarter financial statements [3][10]. - The total amount of credit impairment losses recognized in the third quarter is 2,246,536.01 yuan, while the total asset impairment losses amount to 8,190,168.84 yuan [15]. Impairment Provisions - The total impairment provisions for the third quarter amount to 5,943,632.83 yuan, which will impact the company's total profit before tax [15][16]. - The company has conducted a thorough assessment of its credit and assets, adhering to the principles of prudence in accounting [13][16]. Shareholder Information - The company has approved a stock incentive plan for 2025, which includes granting a total of 1,837,971 shares, representing 1.50% of the company's total share capital [6][8]. - As of the reporting period, the company has completed the granting of 456,327 shares at a price of 21.77 yuan per share [7]. Related Transactions - The company has increased the expected amount for daily related transactions for 2025 by 30 million yuan, with unanimous approval from the board of directors [8].

Core Viewpoint - Dongwei Semiconductor reported significant growth in both revenue and net profit for the third quarter of 2025, indicating strong operational performance and positive market conditions [1] Financial Performance - In Q3 2025, the company achieved a revenue of 348 million yuan, representing a year-on-year increase of 33.26% [1] - The net profit attributable to shareholders for Q3 2025 was 20.97 million yuan, reflecting a year-on-year growth of 53.09% [1] - Basic earnings per share for Q3 2025 stood at 0.17 yuan [1] - For the first three quarters of 2025, the company reported a total revenue of 964 million yuan, which is a year-on-year increase of 41.60% [1] - The net profit attributable to shareholders for the first three quarters was 48.55 million yuan, showing a year-on-year growth of 58.46% [1] - Basic earnings per share for the first three quarters was 0.40 yuan [1]